<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478124</url>
  </required_header>
  <id_info>
    <org_study_id>NPsy-PSP</org_study_id>
    <nct_id>NCT03478124</nct_id>
  </id_info>
  <brief_title>Neuropsychological Evaluation for Early Diagnosis of PSP</brief_title>
  <official_title>The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Generale Di Zona Moriggia-Pelascini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Generale Di Zona Moriggia-Pelascini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to better understand the nature of the cognitive decline in
      Progressive Supranuclear Palsy, the time of its development and the relation with the other
      cardinal features of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical
      supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly
      in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's
      disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive
      deficits are a leading feature of PSP and they actually represent one of the four functional
      core domains in the revised diagnostic criteria. The aim of this study is to better
      understand the nature of this cognitive decline, the time of its development and the relation
      with the other cardinal features of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">March 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMSE</measure>
    <time_frame>1 year</time_frame>
    <description>Mini-Mental State Examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FAB</measure>
    <time_frame>1 year</time_frame>
    <description>Frontal Assessment Battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MoCA</measure>
    <time_frame>1 year</time_frame>
    <description>Montreal Cognitive Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WCST</measure>
    <time_frame>1 year</time_frame>
    <description>Wisconsin Card Sorting Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST</measure>
    <time_frame>1 year</time_frame>
    <description>Stroop Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TMT-A and B</measure>
    <time_frame>1 year</time_frame>
    <description>Trail Making Test Parts A &amp; B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VFT</measure>
    <time_frame>1 year</time_frame>
    <description>Verbal fluency Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ROCF copy and delayed recall</measure>
    <time_frame>1 year</time_frame>
    <description>Rey-Osterrieth complex figure test copy and delayed recall</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RAVLT</measure>
    <time_frame>1 year</time_frame>
    <description>Rey Auditory Verbal Learning Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>1 year</time_frame>
    <description>6 Minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUG</measure>
    <time_frame>1 year</time_frame>
    <description>Timed Up and Go Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BBS</measure>
    <time_frame>1 year</time_frame>
    <description>Berg Balance Scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">112</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>PSP patients</arm_group_label>
    <description>Patients suffering from Progressive Supranuclear Palsy (PSP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD Patients</arm_group_label>
    <description>Patients suffering from Parkinson's disease (PD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive evaluation</intervention_name>
    <description>An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.</description>
    <arm_group_label>PSP patients</arm_group_label>
    <arm_group_label>PD Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        56 PSP patients (PSPp) and 56 PD patients (PDp) were enrolled and matched for sex, age and
        disease duration.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the criteria for idiopathic PD

          -  Patients fulfilling the criteria for PSP

        Exclusion Criteria:

          -  Any other neurodegenerative disorders or medical conditions different from PD / PSP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Frazzitta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, &quot;Moriggia-Pelascini&quot; Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

